Last reviewed · How we verify

NCT04529590

Precise Treatment of Prediabetes and Stage 1 Hypertension

Completed Last updated 1 February 2024
What this trial tests

trial in Diabetes in 2,004 participants. Completed in 30 September 2023.

Timeline
1 October 2020
Primary endpoint
30 October 2020
30 September 2023

Quick facts

Lead sponsorRuijin Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment2,004
Start date1 October 2020
Primary completion30 October 2020
Estimated completion30 September 2023
Sites1 location across China

Conditions studied

Sponsor

Ruijin Hospital

Who can join

Adults 18 to 76, any sex, with Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To identify the occurrence of diabetes, hypertension, cardiovascular and cerebrovascular events and all-cause death in patients with baseline prediabetes and stage1 hypertension after 18 years follow up. To identify whether one or several metabolites can be used as serum markers to judge the prognosis of patients with prediabetes and stage1 hypertension, and to establish the evaluation model of metabolites for the prognosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetes

Currently open trials in the same condition.

Other Ruijin Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04529590.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing